<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038596</url>
  </required_header>
  <id_info>
    <org_study_id>HipMSC-Osteoarthritis</org_study_id>
    <nct_id>NCT01038596</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stromal Cells and Osteoarthritis</brief_title>
  <official_title>Proliferation and Osteogenic Differentiation of Bone Marrow-derived Mesenchymal Stromal Cells From Osteoarthritic Versus Healthy Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis (OA) is one of the most frequent musculoskeletal disorders and represents the
      main indication for total joint arthroplasty. Multipotent mesenchymal stromal cells (MSCs)
      can be easily isolated and culture expanded from bone marrow aspirates and provide an
      excellent source of progenitor cells for cell-based regeneration strategies due to their ex
      vivo differentiation and proliferation capacity. Although there are hints that MSCs derived
      from OA patients may exhibit altered function the role of MSCs with respect to disease
      development and progression of OA is not clearly understood to date. To assess whether
      advanced-stage OA affects MSCs' suitability for musculoskeletal regenerative therapy, in the
      present study, we compare proliferation and differentiation potential of MSCs from
      osteoarthritic versus healthy donors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical data (range of motion of lower limb joints, sociodemographic score dataset, WOMAC
      score, EQ-5D score, Harris Hip Score, radiological evaluation (OA group only), routine
      laboratory parameters, and bone metabolism parameters)

      Osteogenic, chondrogenic, and adipogenic differentiation is proofed qualitatively by cell
      staining

      osteogenic, chondrogenic and adipogenic marker gene expression analysis using quantitative
      real-time RT-PCR

      cell-specific alkaline phosphatase (ALP) activity assay

      large-scale gene expression profile

      Fluorescence-activated cell sorting (FACS)- CD44, CD105 (SH2; endoglin), CD106 (vascular cell
      adhesion molecule; VCAM-1), CD166, CD29, CD73 (SH3 and SH4), CD90 (Thy-1), CD117, STRO-1 and
      Sca-1 [%]
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global Gene expression profile of bone marrow-derived mesenchymal stromal cells from osteoarthritic versus healthy donors</measure>
    <time_frame>after msc isolation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow cytometric analysis of cell surface antigens, Alkaline phosphatase activity, DNA content as measure for cellular proliferation</measure>
    <time_frame>variable 2 days up to 21 days after msc cultivation</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>osteoarthritic donors</arm_group_label>
    <description>pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy donors</arm_group_label>
    <description>age-matched healthy donors</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bone marrow aspirates
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4, mean 67±6 years)
        osteoarthritic and age-matched healthy donors
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  indication for hip THR

          -  primary osteoarthritis of the hip

          -  Patient's consent

        Exclusion Criteria:

          -  secondary osteoarthritis of the hip

          -  Any malignancies

          -  infectious disease

          -  rheumatic disease

          -  osteoporosis

          -  Any additional serious disease complicating the participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Dresden, Orthopaedic Department</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis, mesenchymal stromal cells, proliferation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

